Search

for
Search:

GlossaryGLP-1 receptor agonists

mimic a hormone to regulate blood sugar and promote fullness

GLP-1 receptor agonists are a class of medications that mimic the action of the glucagon-like peptide-1 (GLP-1) hormone, which helps regulate blood sugar levels by enhancing insulin secretion and inhibiting glucagon release. They are commonly used in the treatment of type 2 diabetes and can also promote weight loss by slowing gastric emptying and increasing feelings of fullness.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 190 results

research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

59 citations , August 2021 in “Frontiers in Endocrinology”

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

research Associations Between GLP-1 Receptor Agonists and Alopecia: A Multi-Center Retrospective Analysis and Public Interest Trends

October 2025 in “JEADV Clinical Practice”

GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.

research Alopecia as an Emerging Adverse Effect Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss: A Scoping Review

August 2025 in “Cureus”

GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.

research Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review

October 2025 in “International Journal of Dermatology”

GLP-1 receptor agonists may cause hair loss, but regrowth is rare.

research Hair Loss Associated With Glucagon-Like Peptide-1 Receptor Agonist Use: A Systematic Review

September 2025 in “Cureus”

GLP-1 receptor agonists may cause hair loss, but more research is needed.

View more "glp-1 receptor agonists" in research →

Community Join

5 / 22 results

community A New Hair Loss Drug Could Cure Balding and Reverse Graying

in Research/Science 368 upvotes 1 month ago

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

community Did UCLA Just Cure Baldness? Check this Out!

in Research/Science 969 upvotes 9 months ago

UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.

community Female, 30, PCOS diagnosis, MPB Norwood 2. Endo refuses to give anything other than Spironolactone. Feel like I’m at my wit’s end here.

in Female 55 upvotes 2 years ago

A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

community The end of balding: We may have just found the secret to hair regrowth

in Technology 676 upvotes 7 months ago

MCL-1 is important for hair follicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.

community He used Dutasteride for 20 years. Interview

in Treatment 114 upvotes 1 year ago

Dutasteride has been used for 20 years with some hair thickness improvement but no dramatic regrowth. The user also experimented with minoxidil, tretinoin, and peptides like BPC 157 for potential benefits in hair density and quality.

View more "glp-1 receptor agonists" in community →